

Antibiotic Susceptibility Patterns of Commonly Isolated Bacteria for July 2024-June 2025

Numbers below represent **percent of susceptible isolates** (no. of isolates tested)

WEILER ICU (4WIC, 4ECI, 7N, 7CICU)		n	Ampicillin	Ampicillin-Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin ²	Gentamicin	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin ³	Oxacillin	Penicillin G	Piperacillin-Tazobactam	Tetracycline	Tobramycin	Trimethoprim-Sulfamethoxazole	Vancomycin
Gram Negative	<i>Acinetobacter baumannii</i> complex ¹	13		69%			69%		15%	54%			62%			62%				50%		85%	77%	
	<i>Enterobacter cloacae</i> ¹	11			64%		91%		55%	91%			100%			100%				55%		100%	100%	
	<i>Escherichia coli</i>	66	29%	36%	62%	50%	62%		61%	53%			86%			100%	94%			62%		83%	56%	
	<i>Klebsiella pneumoniae</i>	50		60%	80%	64%	78%		78%	82%			98%			98%	45% ¹			68%		92%	84%	
	<i>Proteus mirabilis</i> ¹	15	73%	80%	100%	0%	100%		100%	73%			67%							100%		73%	93%	
	<i>Pseudomonas aeruginosa</i>	47			68%		83%			88%			94%			82%				73%		1		
	<i>Serratia marcescens</i> ¹	8			1		1		1	1			1			1				1		1	1	
	<i>Stenotrophomonas maltophilia</i> ¹	9						1						1									1	
Gram Positive	<i>Staphylococcus aureus</i>	67				54%					76%		99%					53%	0%		87%		93%	100%
	<i>Staphylococcus epidermidis</i> ¹	19				42%					42%		84%					42%	0%		72%			100%
	<i>Staphylococcus lugdenesis</i> ¹	5				1					1		1					1	1		1			1
	<i>Enterococcus faecalis</i> ¹	9	1												1									1
	<i>Enterococcus faecium</i> ¹	7	1								1				1									1
	<i>Enterococcus faecalis</i> (Urine) ¹	2	1												1									1
	<i>Enterococcus faecium</i> (Urine) ¹	3	1								1				1									1

denotes antibiotics that are not routinely tested against or known to be clinically relevant treatment options for the specific organisms

10⁺ % decrease in susceptibility from 2022-2023 antibiogram

10⁺ % increase in susceptibility from 2022-2023 antibiogram

10⁺ % decrease in susceptibility compared to global inpatient population

10⁺ % increase in susceptibility compared to global inpatient population

1 Organisms with fewer than 30 isolates should be interpreted with caution as small numbers may bias group susceptibilities

2 For *E. faecalis*, daptomycin is not recommended due to cost and the availability of an agent with a narrower spectrum of activity

3 For treatment of uncomplicated urinary tract infection with CrCl > 30mL/min only